Ista Submits Xibrom NDA For Ocular Inflammation
This article was originally published in The Pink Sheet Daily
Executive Summary
Ista has submitted an NDA for Xibrom (bromfenac, .1%) for treatment of ocular inflammation following cataract surgery, the firm announced May 25